Paritaprevir is an inhibitor and a substrate of P-gp, BCRP and OATP1B1/1B3.
Ombitasvir is metabolized by P-gp.
Ritonavir is an inhibitor and a substrate of P-gp; it is also an inhibitor of CYP3A4 and BCRP.
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
J ANTIINFECTIVES FOR SYSTEMIC USE
J05 ANTIVIRALS FOR SYSTEMIC USE
J05A DIRECT ACTING ANTIVIRALS
J05AP Antivirals for treatment of HCV infections
J05AP53 Ombitasvir, paritaprevir and ritonavir
D10745 Ombitasvir, paritaprevir and ritonavir
Drug groups [BR:br08330]
Antiviral
DG03198 Anti-HCV agent
D10745 Ombitasvir, paritaprevir and ritonavir
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
D10745 Ombitasvir, paritaprevir and ritonavir
DG02925 CYP3A5 substrate
D10745 Ombitasvir, paritaprevir and ritonavir
Metabolizing enzyme inhibitor
DG02852 CYP3A/CYP3A4 inhibitor
DG01522 CYP3A4 inhibitor
D10745 Ombitasvir, paritaprevir and ritonavir
Transporter substrate
DG01665 ABCB1 substrate
D10745 Ombitasvir, paritaprevir and ritonavir
DG01913 ABCG2 substrate
D10745 Ombitasvir, paritaprevir and ritonavir
DG02856 SLCO1B1 substrate
D10745 Ombitasvir, paritaprevir and ritonavir
DG02932 SLCO1B3 substrate
D10745 Ombitasvir, paritaprevir and ritonavir
Transporter inhibitor
DG01622 ABCB1 inhibitor
D10745 Ombitasvir, paritaprevir and ritonavir
DG02862 ABCG2 inhibitor
D10745 Ombitasvir, paritaprevir and ritonavir
DG02865 SLCO1B1 inhibitor
D10745 Ombitasvir, paritaprevir and ritonavir
DG02907 SLCO1B3 inhibitor
D10745 Ombitasvir, paritaprevir and ritonavir
Antimicrobials [BR:br08307]
Antivirals
Polyprotein cleavage inhibitor
HCV NS3/4A inhibitor
D10745 Ombitasvir, paritaprevir and ritonavir
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D10745
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D10745
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D10745
Drug transporters
D10745